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Abstract The end of twentieth century has introduced
some changes into T helper (Th) cells division. The iden-
tification of the new subpopulation of T helper cells
producing IL-17 modified model of Th1–Th2 paradigm and
it was named Th17. High abilities to stimulate acute and
chronic inflammation made these cells ideal candidate for
crucial player in development of autoimmune disorders.
Numerous publications based on animal and human models
confirmed their pivotal role in pathogenesis of human
systemic and organ-specific autoimmune diseases. These
findings made Th17 cells and pathways regulating their
development and function a good target for therapy.
Therapies based on inhibition of Th17-dependent pathways
are associated with clinical benefits, but on the other hand
are frequently inducing adverse effects. In this review, we
attempt to summarize researches focused on the impor-
tance of Th17 cells in development of human autoimmune
diseases as well as effectiveness of targeting IL-17 and its
pathways in pre-clinical and clinical studies.
Keywords Th17  IL-17  Autoimmune diseases 
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Introduction
In the late twentieth century some changes in T helper
cell’s classification have been introduced. In 1989 Mos-
mann and Coffman (1989) described the relationship
between functional properties of Th1 and Th2 cells and
cytokines produced by them (Mosmann et al. 2005).
However, in the nineties of the past century a new cyto-
kine, interleukin (IL)-17, was identified (Rouvier et al.
1993; Yao et al. 1995). Subsequently the presence of a
novel Th cell subpopulation (Th17), able to produce IL-17,
was revealed.
There are six known isoforms of IL-17, from A to F, but
Th17 cells are able to produce only IL-17A and IL-17F
(Tesmer et al. 2008). Both of them are pro-inflammatory
cytokines. Some researchers have recently shown that IL-
17A and/or IL-17F are responsible for development of
inflammation in many disorders, especially in autoimmune
diseases like rheumatoid arthritis (RA), psoriasis, juvenile
idiopathic arthritis (JIA), Crohn’s disease and many others
(Adami et al. 2014; Hot and Miossec 2011; Hu et al. 2011;
Piper et al. 2014; Tesmer et al. 2008). This special popu-
lation of CD4? T cells produces also IL-21 (Pelletier and
Girard 2007) and IL-22 (Pan et al. 2013b). Both of them
are pro-inflammatory cytokines; IL-21 helps to restore the
balance between Th17 and Treg cells and IL-22 is a
member of IL-10 cytokine family, which is linked to
chronic inflammation and participates in pathogenesis of
many autoimmune diseases.
Th17, like other Th cells, need specific cytokines and
transcription factors for activation and proliferation.
Specific molecules regulating Th17 cells functions and
properties have become more interesting, after discovery
that Th17 cells take part in pathomechanisms of many
diseases. Since then researchers have tried to find origin
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and function of Th17 cells and have been trying to use
them in therapy. Today we know two ways of activation of
Th17 cells and some factors, which promote and inhibit
their differentiation. Th17 cells can be stimulated with the
use of IL-6/transforming growth factor (TGF)-b (Ghilardi
and Ouyang 2007) or IL-23p40 pathway. Main inhibitors
of Th17 cells are cytokines produced by Th1 and Th2 cells,
interferon (IFN)-c and IL-4, respectively (Stumhofer et al.
2007). Noack and Miossec (2014) have described also
Th17 reciprocally connections with Treg population. Cai
et al. (2012) demonstrated in mouse model, that in exo-
somes, TGF-b1 delayed inflammatory bowel disease
(IBD). At the same time, in lymph nodes, it increased
proportion of Foxp3? Tregs and decreased percentage of
Th17. The interaction between Th17 and Treg populations
is probably very important in pathogenesis of autoimmune
diseases, because deviation of critical balance in favor of
Th17 cells significantly enhances the severity of disease.
In this review, we describe recent progress in under-
standing of the involvement of Th17 cells and related
cytokines in pathogenesis of some autoimmune diseases.
To facilitate finding information about particular disorder
each of them was described separately. Finally, we
emphasize recent results considering effectiveness of
therapies targeting Th17 pathways.
The Role of Th17 Cells and Related Cytokines
in Pathogenesis of Autoimmune Diseases
Systemic Autoimmune Diseases
Substantial progress in understanding of Th17 development
and the effects of IL-17 signaling in immune responses has
revealed their potential role in human autoimmune dis-
eases. Systemic autoimmune diseases are in majority
characterized by the loss of B cells control, production of
autoantibodies, and formation of immune complexes,
which contribute to tissue damage.
Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoim-
mune disorder that may affect the skin, joints, kidneys,
brain, heart, blood and other organs. There is growing
evidence in both mouse and human models that IL-17 and
Th17 cells play an important role in SLE progression.
Increased number of T cells producing IL-17 was found in
peripheral blood and inflamed organs of patients with SLE
(Crispı´n et al. 2008; Henriques et al. 2010; Shah et al.
2010). Plasma concentration of IL-17 was increased in
new-onset patients and during SLE flares rather than in
patients with inactive disease (Chen et al. 2010b;
Henriques et al. 2010; Yang et al. 2009). Studies consid-
ering involvement of IL-17 in pathogenesis of SLE also
proved that concentration of IL-17 correlates with severity
of the disease (Chen et al. 2010b; Doreau et al. 2009; Shah
et al. 2010). IL-17? T cells were also capable to secrete
tumor necrosis factor (TNF), IL-2 and IFN-c, the cytokines
also associated with disease severity (Chen et al. 2010b;
Crispı´n et al. 2008). Doreau et al. (2009) showed that IL-17
alone or in combination with B cell-activating factor con-
trolled the survival and proliferation of B cells and their
differentiation into immunoglobulin-secreting cells sup-
porting development of SLE symptoms. Mitoma et al.
(2005) demonstrated that decreased expression of IL-21R
on B lymphocytes in SLE was significantly associated with
nephritis and high-titer anti-double-strand DNA antibodies.
Some authors also consider that imbalance between Th17
cells and Th1 or Treg lymphocytes caused by disorders in
cytokines regulation could be important in development of
SLE. The results of genetic studies suggest that genetic
variations and distinct gene expression profiles of cytokines
secreted by Th17 cells could contribute to the risk of SLE
(Pan et al. 2013a; Yu et al. 2011). Also IL-23, which is one
of the main cytokines responsible for development,
expansion, and proliferation of Th17 cells, plays an
important role in pathogenesis of SLE. Du et al. (2014)
showed that the level of IL-23 was elevated in patients with
SLE. They also demonstrated the correlation between the
increased level of IL-23 and renal disease in SLE. This
correlation was also revealed in 2012 by other group of
investigators. Kyttaris et al. (2010) observed that IL-23R
deficiency prevented the development of nephritis in lupus-
prone mice. Therefore, IL-23 is considered to be a potential
biomarker for renal involvement in SLE and a potential
therapeutic target (Du et al. 2014).
Rheumatoid Arthritis
Rheumatoid arthritis (RA) is characterized by the chronic
inflammation of the synovial membrane. Cell’s interactions
induce pro-inflammatory cytokines’ production which in
turn activates the mechanisms leading to cartilage and bone
destruction. It was confirmed that IL-17 could drive
inflammation of joints of patients with RA and could be
produced locally in inflamed synovium (Chabaud et al.
1999). Cytokine milieu found within the joints promotes
Th17 differentiation, because of high levels of IL-6, IL-12,
but not IL-23 and a relatively low abundance of TGF-b
(Nistala et al. 2010). Increased serum level of IL-17 was
also noticed especially in treatment-naı¨ve patients or
patients with systemic symptoms (Liu et al. 2012; Ros¸u
et al. 2012). Interestingly, Arroyo-Villa and coworkers
(2012) reported significantly lower percentage of circulat-
ing Th17 cells and a lower CD4-derived IL-17 secretion in
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early RA patients in comparison with healthy controls.
Additionally, percentage of circulating Th17 cells nega-
tively correlated with a-CCP titer. On the other hand, they
also confirmed that there was no difference between
established RA patients and healthy individuals. Addi-
tionally, they noticed that decreased number of Th17
lymphocytes in peripheral blood of patients was raised
anew after one year of treatment with methorexate. Con-
trary to these results Zhang et al. (2012) noticed increased
percentage of Th17 in patients with the mean disease
duration of 8.9 ± 3.9 years. In the well-designed 2-year
prospective study Kirkham and colleagues (2006) showed
that in RA associated joints’ destruction, IL-17 effects were
best seen in patients with shorter disease duration, and IL-
1b effects were best pronounced in patients with longer
disease duration. Recruitment of Th17 cells to inflamed
joint seems to be dependent on expression of CCR6 on
these lymphocytes and production of CCL20 by synovio-
cytes (Hirota et al. 2007). Th17 activity correlates with
other laboratory parameters of disease activity as well as
with severity of clinical symptoms (Kim et al. 2013;
Metawi et al. 2011; Ros¸u et al. 2012). In the course of RA
IL-17 and Th17 cells are not only inflammation inducers
but they also activate mechanisms leading to joint
destruction. Th17 cells are potent inducers of tissue-de-
structive enzymes, pannus growth, osteoclastogenesis,
angiogenesis (Ito et al. 2011; Moon et al. 2012; Pickens
et al. 2010; van Hamburg et al. 2011). The destructive
mechanisms influence joint’s tissues and are mediated by
different pathways associated with IL-17. Osteoclasts can
be differentiated via COX-2-dependent PGE2 synthesis
(Ito et al. 2011; Kotake et al. 1999), while fibroblasts
activation and proliferation are mediated by mTOR and
MAPK p38 signaling (Kehlen et al. 2002; Saxena et al.
2011). The study of Sato et al. (2006) suggests that Th17
cells do not act directly on osteoclast precursor cells,
although they expressed RANKL. Induction of osteoclasts
is rather associated with osteoclastogenesis-supporting
cells, possibly through IL-17-mediated induction of
RANKL on osteoblastic cells and dendritic cells (Page and
Miossec 2005; Sato et al. 2006). In the context of thera-
peutic targeting of IL-17 in RA, it seems to be important
that Th17 cells act rather TNF independently under
arthritic conditions (Koenders et al. 2006). Studies con-
sidering influence of anti-TNF treatment on Th17 cells led
to inconsistent results. Notley et al. (2008) showed in
mouse model of RA that inhibition of TNF with soluble
receptor or monoclonal antibodies (mAbs) led to increased
production of IL-17 and expansion of IL-17?/CD4? cells
in lymph nodes. Surprisingly, percentage of Th17 cells
infiltrating joints was lower after treatment and it was
associated with reduced arthritis severity. Park et al. (2012)
reported that IL-17 production in inflamed joint was
promoted by TNF-like weak inducer of apoptosis. Con-
tradictory results describing role of IL-22 and its
interaction with IL-17 were observed in arthritis. Zhang
et al. (2011) noticed that increase of Th17 cells was fol-
lowed by proportional elevation of number of IL-22
producing cells and both parameters correlated with dis-
ease activity. On the other hand, recent publication of van
Hamburg et al. (2013) reported that IL-17A/Th17 cell-
mediated synovial inflammation was independent on IL-22
and Th22 cells.
The role of balance between pro-inflammatory Th17
cells and regulatory T lymphocytes in pathogenesis of
autoimmune diseases has been repeatedly emphasized
(Samson et al. 2012). Wang et al. (2012) and Niu et al.
(2012) showed in their research the imbalance of Th17/
Treg in the peripheral blood of patients with RA. Gener-
ation of Th17 cells is promoted by proinflammatory
cytokines like IL-6 and IL-23 while the concentrations of
TGF-b and the number of Treg cells are decreased in RA
patients. According to Wang and co-workers (2012), these
combined changes contributed to autoimmunity triggering
and inflammation induction. Interestingly, Jiao et al. (2013)
showed importance of myeloid-derived suppressor cells
(MDSC) in controlling of Th17 cells, although MDSC
number was correlated neirther with plasma level of IL-6
and IL-17 nor with the mRNA level of RORct. The authors
showed that MDSC negatively correlated with TNF level,
what could prove that this population is in control of two
independent mechanisms of RA pathogenesis related to
increased secretion of TNF and IL-17. Moreover, some
groups showed that proliferation of Th17 cells is activated
by phosphorylation of signal transducer and activator of
transcription 3 (STAT3) (Dong et al. 2014; Son et al.
2014). Inhibition of STAT3 leads to decrease of Th17 cell
frequency and in consequence the number of Tregs is
elevated.
IL-6 controls differentiation of Th17 cells via binding
IL-6 to the IL-6 receptor’s a chain and to gp130, both of
which mainly activate JAK1 and STAT3 (Tamiya et al.
2011). Surprisingly use of pyridone 6, a pan-JAK inhibitor,
led to exacerbation as well as amelioration of autoimmune
diseases (Nakagawa et al. 2011; Yoshida et al. 2012). The
effect of inhibition of STAT3 activation and IL-6 signaling
seems to be depending on other cells and cytokines
involved in pathogenesis of particular disease. For exam-
ple, IL-7 is another cytokine regulating Th cells
differentiation via JAK and blockade of IL-7Ra potently
inhibited autoimmune joint inflammation by reduction of
Th17 activity (Hartgring et al. 2010). Activation of STAT3
can directly induce the production of IL-17 as well as IL-
21, which are autocrined by differentiating Th17 cells and
expand the differentiation of Th17 (Chen et al. 2007). Zhou
et al. (2012) showed that fenobirate, and some other
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PPARa agonists, suppressed differentiation of Th17 cells
in vitro via reducing of STAT3 activation and IL-21
secretion. RORct was shown to be crucial factor for the
differentiation of Th17 cells. Sustained activity of this
factor is required for the function of differentiated Th17
lymphocytes. RORct belongs to nuclear hormone receptor
family, which makes it a good target for small molecule
inhibitors, e.g. digoxin and ursolic acid (Huh et al. 2011;
Huh and Littman 2012). Collagen-induced arthritis (CIA)
is a popular animal model used for testing of Th17 tar-
geting therapies. The crucial factor for development of
arthritis in collagen-immunized mice is IL-23. However,
recently published paper by Cornelissen et al. (2013) has
shown that IL-23 is not a critical factor during the effector
stage of CIA. Their results suggest that specific anti-IL-
23p19 antibodies may not be beneficial as a therapeutic
regime after onset of autoimmune arthritis for RA patients.
On the other hand, T-cell-mediated arthritis relapses in
patients with RA and might be controlled by neutralization
of IL-23.
Th17-dependent pathways are controlled not only by
cytokines, but also by neuromediators. Cholecystokinin
octapeptide (CCK-8) and vasoactive intestinal peptide are
the neuropeptides significantly suppressing the incidence
and severity of CIA in mice. These factors also inhibit
dendritic cell-mediated Th17 polarization (Deng et al.
2010; Li et al. 2011). Antagonist of D1-like receptor
inhibits cartilage destruction in a human RA/SCID mouse
chimera model and this effect is associated with decrease
of dopamine-mediated IL-6 and IL-17 (Nakano et al.
2011).
Food products and diet could be used for control of
Th17 activity. Kim et al. (2008) showed that rat fed with
green tea significantly reduced the severity of arthritis
compared with the water-fed controls and this effect was
associated with decreased concentration of IL-17 and
increased level of IL-10. Another plant derived agents—
daphnetin and grape seed proanthocyanidin extract also
reduced symptoms associated with CIA via decrease of IL-
17 production (Cho et al. 2009; Tu et al. 2012). Plant
extracts influencing function of Th17 cells and ameliorat-
ing severity of arthritis are not the only immunomodulatory
substances taken from traditional medicine. Tanaka et al.
(2012) showed in mouse model of arthritis that Brazilian
propolis declined IL-17 expression measured by ELISA
and real-time PCR methods. Additionally, Okamoto et al.
(2012) noticed that propolis decreased differentiation of
IL-17 producing cells and this effect was mediated via
suppression of the IL-6-induced phosphorylation of
STAT3.
The novel synthetic agents can also influence differen-
tiation and activation of Th17 lymphocytes and attenuate
rheumatoid inflammation in mice. In this group there is
also all-trans retinoic acid (ATRA) (Kwok et al. 2012),
which reduces IL-17 level and promotes activation of Treg
cells in ATRA-treated mice. The next synthetic agent is
tylophorine analog (NK-007) (Wen et al. 2012). It sup-
presses production of IL-6 and IL-17A in joints of mice
with CIA. Similarly, polymerized-type I collagen causes
decrease of IL-17A level and up-regulates the number of
Tregs and Th1 cells (Furuzawa-Carballeda et al. 2012).
Chen et al. (2010a) demonstrated in CIA mice that the
suppression of PGE2 EP(4) receptor leads to decrease of
cytokines production by Th1 and Th17 cells. Moreover,
Moon et al. (2014) showed that rebamipide, a gastropro-
tective agent, is able to reduce inflammation in CIA mice
by the recovery from an imbalance between Th17 and Treg
cells.
Cyclosporine A (CsA) is an immunosuppressive drug
used in transplantation medicine and treatment of autoim-
mune diseases. CsA reduces expression of IL-17 at protein
and at mRNA levels in the cells isolated from the blood of
patients with RA (Zhang et al. 2008). Similar effect was
described in patients with Vogt-Koyanagi-Harada syn-
drome treated with CsA combined with corticosteroids
(Liu et al. 2009). Contrary to these results, Abadja et al.
(2009) reported that CsA did not inhibit IL-17 expression
in cultured human peripheral blood mononuclear cells.
Also, Lemaıˆtre et al. (2013) showed that CsA failed to
inhibit IL-17 production in mice after heterotopic trachea
transplantation.
Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA) is a heterogeneous and
multifactorial autoimmune pediatric disease characterized
by chronic joint inflammation with onset age younger
than 16 years. It is the most common chronic rheumatic
disease in childhood and an important cause of disability.
JIA has different subtypes that are defined based on the
number of inflamed joints during the first 6 months of
disease and the extra-articular involvement. In JIA
patients, similarly to adult patients with RA, joint
microenvironment promotes Th17 differentiation. Cosmi
et al. (2011) noticed increased number of Th17/Th1 cells
described as producing both IFN-c and IL-17A, but not
IL-17A alone in children with oligoartricular onset of JIA.
They also reported that CD4?/CD161? cells producing
only IL-17A can easily shift into cells producing IFN-c
and IL-17A or IFN-c alone. Synovial Th17 cells produce
also IL-22 and IFN-c, but not IL-4. The number of T cells
producing IL-17 is higher in the joints of patients with the
more severe phenotype of disease (Nistala et al. 2008).
Expression of CCR6 and response to CCL20 were also
confirmed in JIA patients, so it is in accordance with
described mechanisms of Th17 cell migration in RA
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patients. In JIA patients it was also confirmed that
reciprocal relations between Th17 and Treg cells are
crucial in development of chronic inflammation. Systemic
subtype of JIA is associated with anomalies in the innate
immune system leading to the loss of control of alterna-
tive secretory pathway in phagocytes. Omoyinmi et al.
(2012) noticed increased percentage of IL-17?CD3? both
CD4? and CD4- comparing to healthy age matched
controls, but not in comparison to oligoarticular JIA.
Sjo¨gren Syndrome, Systemic Sclerosis, Ankylosing
Spondylitis
The presence of Th17 lymphocytes and IL-17 at the protein
and mRNA levels were confirmed in inflamed salivary
glands and peripheral blood of patients with Sjo¨gren syn-
drome (Ciccia et al. 2012; Katsifis et al. 2009; Maehara
et al. 2012). Increased activity of Th17 cells was associated
with low number of T regulatory cells and higher con-
centration of IL-21, IL-22, IL-23 (Ciccia et al. 2012; Kang
et al. 2011). Alunno et al. (2013) noticed that CD4-CD8-
T cells producing IL-17 from patients with Sjo¨gren syn-
drome were in vitro resistant to corticosteroids.
Additionally influence of IL-17R on human salivary cells
lines was confirmed and IL-17 stimulated salivary gland
cells to secrete pro-inflammatory IL-6 and IL-8 (Sakai
et al. 2008).
IL-17A-producing T cells are characteristically
increased in peripheral blood of patients with systemic
sclerosis (SSc) and they are characterized by expression of
chemokine receptor CCR6 responsible for with skin- and
lung-homing capabilities (Radstake et al. 2009; Truchetet
et al. 2011). Results describing plasma level of IL-17A
remain ambiguous. Murata et al. (2008) described elevated
concentration of IL-17A in the blood of SSc patients. On
the contrary Radstake et al. (2009) did not find significant
differences in IL-17A concentration between SSc individ-
uals and healthy controls. The increased percentage of
circulating Th17 cells is rather independent on type or
stage of disease. Additionally, frequency of Th17 cells in
bronchoalveolar lavage fluid of patients with SSc was
associated with lungs’ involvement (Fenoglio et al. 2011;
Meloni et al. 2009). The presence of Th17 in blood and
affected tissues seems to be crucial for SSc development.
Surprisingly, the recent study of Truchetet et al. (2013) has
shown that the presence of IL-17A? cells correlates
inversely with the extent of skin fibrosis. Th17 cells may
counterbalance fibrosis via induction of extracellular
matrix degrading enzymes, inhibition of collagen synthe-
sis, and myofibroblast differentiation, while favoring a pro-
inflammatory microenvironment.
The number of Th17 cells and concentration of IL-17
and IL-23 are increased in the peripheral blood of patients
with ankylosing spondylitis (Mei et al. 2011; Shen et al.
2009; Zhang et al. 2012). IL-17 producing cells expressed
phenotype of memory cells CD4?CD45RO? and were
positive for CCR6 (Shen et al. 2009). Percentage of Th17
cells and concentrations of IL-17 and IL-23 positively
correlated with disease activity and were increased in
patients not responding to anti-TNF therapy (Xueyi et al.
2013).
Organ-Specific Autoimmune Diseases
The autoimmune organ-specific diseases are mediated by
specific immune response directed against antigens char-
acteristic for particular tissues. The role of Th1 and Th2 in
this type of disorders was quite well established. Th17
seems to be a new player in organ specific autoimmunity.
Type 1 Diabetes
Type 1 diabetes (T1D) is an autoimmune disease in which
insulin-producing b cells in the pancreatic islets are
destroyed by cytotoxic T lymphocytes, resulting in defi-
ciency of insulin and chronic hyperglycemia requiring
lifelong dependence on insulin supplementation. Upregu-
lation of Th17 immunity in peripheral blood and lymph
nodes of patients with T1D was observed (Ferraro et al.
2011; Honkanen et al. 2010). Dysregulation of Th17 and
Treg interaction was also confirmed. More interestingly,
Marwaha et al. (2010) showed that CD45RAneg/CD25mid/
FOXP3low lymphocytes lost regulatory abilities and
secreted IL-17, what made them pro-inflammatory cells.
Autoimmune Thyroid Disorders
The most common autoimmune thyroid diseases (AITD)
are Graves’ disease in young adults and Hashimoto’s dis-
ease in children and young women. The proportion of
peripheral Th17 cells in patients with AITD was higher
than in control subjects and it was dependent on disease
activity and severity (Figueroa-Vega et al. 2010; Kim et al.
2012; Nanba et al. 2009). However, Zheng et al. (2013)
reported increased expression of IL-17 mRNA also in
euthyroid patients with Graves’ disease and it was upreg-
ulated after stimulation with IL-23. Bossowski et al. (2012)
examined a group of children with AITD and they found
increased percentage of CD4?IL-17? cells in children with
untreated Hashimoto’s disease, but not in children with
Graves’ disease. Additionally, percentage of CD4?IL-17?
cells positively correlated with titers of anti-thyroid per-
oxidase immunoglobulins. Shi et al. (2010) suggested that
Th17 cells can play a central role in pathogenesis of
Hashimoto’s disease rather than Th1 cells. Thesr
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conclusions were based on confirmed higher expression of
IL-17 mRNA than IFN-c mRNA in peripheral blood cells.
Unfortunately, authors did not include any data about
duration of disease what in combination with age of
patients ranged 23–60 leading to conclusions that patients
were rather not in active phase of lymphocytic thyroiditis.
This could explain low activity of Th1 response and rela-
tive predominance of IL-17 producing cells.
Multiple Sclerosis, Myasthenia Gravis
Multiple sclerosis (MS) is a chronic inflammatory disease
with destruction of myelin shift in central nervous system.
The blood–brain barrier (BBB) disruption is an early and
main event in MS development. Autoreactive Th17 cells
can disrupt tight junction proteins in the central nervous
system endothelial cells and migrate through the BBB and
this effect is mediated via IL-17 and IL-22 (Kebir et al.
2007). Accumulation of Th17 cells was found in cere-
brospinal fluid of patients with MS relapse. The number
of Th17 was higher in affected individuals than in
patients in remission or patients with other central ner-
vous system pathologies (Brucklacher-Waldert et al.
2009; Schirmer et al. 2013). These cells were character-
ized by high expression of activation markers and
molecules involved in T cell adhesion to endothelium.
Christensen et al. (2013) reported that percentage of cir-
culating Th17 cells, identified as CD4?IL-23R? cells, was
increased in patients with more severe type of MS. These
results stay in accordance with previous results describing
increased percentage of CD3?CD4?IL-17? and CD3?-
CD8?IL-17? cells in patients with MS (Wang et al.
2011).
Several studies were focused on changes in IL-17 serum
concentration during therapy with IFN-b. All studies con-
firmed decrease of IL-17 induced by IFN-b, although in
studies analyzing response to therapy this effect was
described only in patients responding to therapy (Esendagli
et al. 2013; Ku¨rtu¨ncu¨ et al. 2012; Kvarnstro¨m et al. 2013).
Additionally, patients with high serum IL-17A levels did
not respond well to IFN-b therapy (Balasa et al. 2013).
Multiple sclerosis is still incurable disease, where
blockade of Th17 cells could be useful in treatment, so a
set of studies utilizing experimental autoimmune
encephalomyelitis (EAE) as animal model of demyelinat-
ing disorders was conducted. Nakano et al. (2008) showed
that use of a dopamine D1-like-receptor antagonist inhib-
ited dendritic cell-mediated Th17 differentiation and
prevented development of EAE as well as had therapeutic
effect in mice model.
Similarly to experiments focused on arthritis also in
autoimmune brain disorders we could control activity of
Th17 cells with some food ingredients. Active ingredient of
green tea epigallocatechin-3-gallate also reduced clinical
symptoms of EAE in dose-dependent manner and this
result was due to reduced production of Th17 associated
cytokines and decreased percentage of CD4? cells pro-
ducing IL-17 (Wang et al. 2012). Similar results were
observed in mice treated with ghrelin, anatabine, erioca-
lyxin, salmon cartilage proteoglycans (Lu et al. 2013; Paris
et al. 2013; Sashinami et al. 2012; Souza-Moreira et al.
2013).
Roche et al. (2011) have shown that IL-17 concentration
was higher in myasthenia gravis patients compared with
controls and it positively correlated with anti-acetyl-
cholinesterase receptor antibody titers.
Inflammatory Bowel Diseases
Crohn’s disease and ulcerative colitis are chronic IBDs
thought to be caused by an abnormal immune response
directed against normal constituents of the intestinal flora.
IL-17 expression and percentages of Th17 and Th1/Th17
in the inflamed mucosa and serum was increased in IBD
patients (Fujino et al. 2003; Nielsen et al. 2003; Rovedatti
et al. 2009). Surprisingly, Rovedatti et al. (2009) reported
that production of IFN-c in inflamed mucosa of patients
with ulcerative colitis and Crohn’s disease was equivalent
to normal mucosa and that TGF-b inhibited its production,
but did not downregulate production of IL-17. On the
other hand, Kobayashi et al. (2008) reported that the
transcripts for Th17-related cytokines were more abundant
in ulcerative colitis than in Crohn’s disease when the two
diseases were compared and IL-23 enhanced production of
IL-17 in lamina propria of patients with ulcerative colitis,
while IFN-c in patients with Crohn’s disease. Based on
these data, authors suggested that ulcerative colitis may
actually be classified as a Th17 disease, while Crohn’s
disease remains a Th1 disease. Similar results were
reported for peripheral blood cells (Raza and Shata 2012;
Veny et al. 2010). Although, other researchers confirmed
activation of Th17 pathway in intestinal mucosa and
mesenteric lymph nodes in patients with Crohn’s disease
(Hovhannisyan et al. 2011; Ho¨ltta¨ et al. 2008; Sakuraba
et al. 2009).
Animal models confirm that Th17 cells and cytokines
associated with this population play crucial role in devel-
opment of IBD and show great potential as targets for
therapy of autoimmune bowel’s diseases. Fina et al. (2008)
studied the potential influence of IL-21 on Th17 subpop-
ulation and development of gut inflammation. Researchers
demonstrated that IL-21-deficient mice were protected
against colitis and were unable to increase the number of
Th17 cells. Moreover, neutralization of IL-21 in wild-type
mice with the use of anti-IL-21 antibody decreased the
level of IL-17. However, there are some papers displaying
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differences between suppression of IL-17A and IL-17F.
The development of acute mucosal inflammation was
impossible in trinitrobenzene sulfonic acid induced colitis
in mice with IL-17RA deficiency (Wallace et al. 2014).
However, in a dextran sodium sulfate model of colitis IL-
17F deficiency suppressed mucosal inflammation, but the
lack of IL-17A stimulation caused exacerbation of IBD.
Indeed, IL-17A may be protection factor against the
development of IBD, and IL-17F may contribute to
mucosal inflammation. However, this concern should be
deeply investigated, because there are also some results
suggesting that IL-17A exacerbates IBD. Zhang et al.
(2014) showed, that heme oxygenase-1 (HO-1) decreased
the number of Th17 cells and causes an increase of Treg
population in murine model of acute experimental colitis.
HO-1 switched the naı¨ve T cells to Tregs and reduced the
expression of RORct and level of IL-17A. Therefore, HO-1
might provide a novel therapeutic target in IBD.
Psoriasis
Psoriasis is a chronic inflammatory skin disease associated
with complex skin inflammatory process resulting in ker-
atinocyte hyperplasia. Increased frequency of Th17 cells
was confirmed in skin lesions and peripheral blood of
patients with psoriasis (Kagami et al. 2010; Lowes et al.
2008). Arican et al. (2005) showed that serum concentra-
tion of IL-17 did not differ from healthy donor, but proved
significant correlation with disease activity. These results
are not corresponding with the Coimbra et al. (2010) study
reporting increased IL-17 concentration in psoriatic
patients when compared to healthy individuals. Addition-
ally, the level of IL-17 lowered during UV therapy and it
was followed by improvement of clinical symptoms.
Treatment with soluble TNF receptor exacerbates murine
psoriasis-like disease and symptoms are related to
increased expression of the Th17 associated cytokines such
as IL-1b, IL-6, IL-17, IL-21, IL-22, and reduction of Treg
cells (Ma et al. 2010).
The systemic and local activity of IL-17 and Th17
seems to be important part of development of autoimmune
reaction. The ability to induce pro-inflammatory function
of the cells outside immune systems, e.g. synovial cells, is
one of the factors leading to chronic inflammation. Dis-
turbances in balance between Th17 lymphocytes and
regulatory cells (Treg and myeloid derived suppressor
cells) are described in the majority of autoimmune dis-
eases. Correlation between disease activity and
concentration of IL-17 or percentage of Th17 in the
peripheral blood or other body fluids could be additional
laboratory parameter used in clinical prognosis and moni-
toring of clinical course of the disease.
Th17 Lymphocytes and Their Pathways as Target
for Therapy: Clinical Trials
Although the role of Th17 lymphocytes in etiology and
pathology of human diseases is quite different and multi-
faceted, both in vitro and in vivo studies have clearly
demonstrated the pivotal role of IL-17 in the pathogenesis
of various diseases, making IL-17 a perfect target for
therapeutic procedures. On the basis of pre-clinical studies,
immunologists predicted that blocking of IL-17/IL-17R or
cytokines that promote Th17 induction or activation (IL-1,
IL-6 or IL-23) could be beneficial mainly in patients with
chronic inflammatory diseases. The mAbs targeting these
pathways and potential use in autoimmune diseases is
shown in Fig. 1. On the other hand, questions and skepti-
cism surround the usefulness of animal models as direct
predictors of potential therapeutics for IL-17-based drugs,
so in consequence the results of human clinical trials tar-
geting this pathway have been fervently awaited.
In patients with psoriasis or IBDs, treatment with dif-
ferent TNF inhibitors enhances Th17 activity in blood,
whereas in the inflamed tissues of responding patients, it
induces a potent shut down of Th17-Th1 cytokines (Bose`
et al. 2011). Sugita et al. (2012) showed that anti-
TNF chimeric antibody (Infliximab) inhibited Th17 dif-
ferentiation in uveitis patients with Behc¸et’s disease.
Downregulation of Th17 number and functions seems to be
important to achieve therapeutic effect of anti-TNF treat-
ment in patients with RA. Studies based on human
peripheral blood cells showed that number of IL-17 pro-
ducing lymphocytes and concentrations of cytokines
associated with Th17 development and functions are
decreased in patients who responded to treatment, while in
non-responding patients these levels and functions were
elevated (Alzabin et al. 2012; Chen et al. 2011; Zivojinovic
et al. 2012). Additionally, the study of van Hamburg et al.
(2012) suggested that 1,25(OH)2D3 could be crucial for
suppression of Th17 cells by anti-TNF treatment. Also
combination of TNF inhibitors and methotrexate is more
efficient in downregulation of Th17 response than soluble
TNF receptor alone (Lina et al. 2011).
The majority of conducted clinical trials were focused
on psoriasis, what led to approval of ustekinumab (fully
human IgG1 mAb against p40 subunits of IL-12/IL-23) for
treatment of moderate to severe plaque psoriasis (Patel
et al. 2013; Wofford and Menter 2014). Moreover, the
usefulness of ustekinumab was also evaluated in other
immune-mediated diseases such as psoriatic arthritis, MS
and Crohn’s disease. Results of these trials are summarized
in Table 1. In Crohn’s disease the effectiveness of ustek-
inumab was achieved most notably in patients who had
received previously biological therapy. Other researchers
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showed that the clinical response was better in ustek-
inumab group than in placebo series in patients resistant to
TNF inhibitors (Toussirot et al. 2013; Tuskey and Behm
2014). The study comparing ustekinumab with etanercpet
showed ustekinumab’s superiority to high-dose etanercept
in managing of moderate-to-severe psoriasis (Griffiths
et al. 2010). However, a phase 2 clinical trials investigating
efficacy of ustekinumab in MS displayed its inefficiency in
Fig. 1 Drugs targeting Th17 pathways and their use in human diseases
Table 1 Clinical studies of ustekinumab in psoriasis, psoriatic arthritis, Crohn’s disease, and multiple sclerosis
Study Immune-mediated disease Study design Results
Krueger et al. (2007) Psoriasis Phase II Ustekinumab: 52–81 %
Placebo: 2 %
Leonardi et al. (2008) (PHOENIX 1) Psoriasis Phase III Ustekinumab: 67 %
Placebo: 3 %
Papp et al. (2008)
(PHOENIX 2)
Psoriasis Phase III Ustekinumab: 67–76 %
Placebo: 4 %




Gottlieb et al. (2009) Psoriatic arthritis Phase II Group 1 (ustekinumab then placebo)
versus group 2 (placebo then
ustekinumab) 42 vs 14 %
Sandborn et al. (2008) Crohn’s disease Phase II Ustekinumab: 49 %
Placebo: 40 %
Sandborn et al. (2012) Crohn’s disease Phase III Ustekinumab: 36–39 %
Placebo: 23.5 %
Segal et al. (2008) Multiple sclerosis Phase II No difference between any ustekinumab
groups vs placebo
Results are presented as the percentage of patients who reached the primary endpoint [a 75 % reduction in the Psoriasis Area and Severity Index
score (PASI75)] (Toussirot et al. 2013)
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reducing the number of enhancing lesions (Ghosh 2012;
Scherl et al. 2010). Despite encouraging results showing
clinical benefits of IL-17 and IL-23 inhibition, recently
published meta-analyses have underlined higher number of
major adverse effects in comparison to placebo group and
suggested that patients shall be monitored for these
potential safety signals (Langley et al. 2013; Spuls and
Hooft 2012; Tzellos et al. 2013). Clinical trials focused on
other mAbs are summarized in Table 2.
IL-12/23p40 pathway is quite popular in therapy for
autoimmune diseases. There are some more pharmaceutical
substances using this pathway to inhibit Th17 cells. Bri-
akinumab is one among them. Reich et al. (2011) showed
in third phase clinical trial that it can be more effective in
psoriasis than methotrexate. It also caused more adverse
events; however the difference was statistically
insignificant.
Brodalumab has been proposed for therapy of psoriatic
arthritis. It is a human monoclonal anti-IL-17A receptor
antibody. The results of second phase clinical trial dis-
played that brodalumab improved symptoms in patients
with psoriatic arthritis compared to placebo group (Mease
et al. 2014). Ixekizumab (LY2439821) has been evaluated
in second phase clinical study of RA (Genovese et al. 2014)
and chronic plaque psoriasis (Tham et al. 2014). This
humanized mAb selectively binds to IL-17A and neutral-
izes this pro-inflammatory cytokine. Furthermore,
ixekizumab was proved to be effective also in difficult-to-
treat areas, e.g. scalp and nails (Spuls and Hooft 2012).
Secukinumab (AIN457, a recombinant, highly selective,
fully human IgG1 k mAb against IL-17A) was shown to
improve clinical symptoms in patients with psoriasis, RA
and noninfectious uveitis. Moreover, it enabled reduction
of symptoms in psoriatic arthritis and ankylosing
spondylitis. In the second phase clinical trial was shown,
that in both cohorts: psoriasis/psoriatic arthritis and RA,
patients treated with secukinumab have shown more
effective therapeutic response in comparison to placebo
group. Studies displayed improvement of rates such as
psoriasis area and severity index scores in psoriasis patients
and rate of American College of Rheumatology 20 score in
RA. Rates of adverse events (AEs) and serious AEs were
Table 2 Clinical studies for using Th17 pathways as a target for therapy
Agent Target Trial phase Disease References
Ustekinumab IL-12/IL-23p40 I Psoriasis Kauffman et al. (2004)
I Psoriasis Gottlieb et al. (2007)
II Psoriasis Krueger et al. (2007)
III Psoriasis Griffiths et al. (2010)
III Psoriasis Papp et al. (2008)
III Psoriasis Leonardi et al. (2008)
I Multiple sclerosis Kasper et al. (2006)
II Multiple sclerosis Segal et al. (2008)
Briakinumab IL-12/IL-23p40 III Psoriasis Eggleton et al. (2011)
III Psoriasis Kauffman et al. (2004)
Brodalumab IL-17RA II Psoriasis Gottlieb et al. (2007)
Ixekizumab IL-17A and IL-17A-IL-17F
hetoridmers
II Psoriasis Krueger et al. (2007)
I Rheumatoid arthritis Papp et al. (2008)
Secukinumab IL-17A II Psoriasis Leonardi et al. (2008)
II Psoriasis Kasper et al. (2006)
II Psoriatic arthritis Chioato et al. (2012)
II Rheumatoid arthritis Krueger et al. (2007)
II Psoriasis/rheumatoid arthritis/
uveitis
Leonardi et al. (2008)
II Crohn’s disease Hueber et al. (2012)
III Noninfectious uveitis Dick et al. (2013)
I Vaccinated healthy adults Chioato et al. (2012)
Tocilizumab IL-6R Approved as therapy Rheumatoid arthritis Herna´ndez et al. (2013)
Anakinra IL-1R Approve as therapy Rheumatoid arthritis Cavagna and Taylor (2014)
Olokizumab IL-6 II Rheumatoid arthritis Tanaka and Mola (2014)
Sarilumab IL-6Ra II Rheumatoid arthritis Huizinga et al. (2014)
Sirukumab IL-6 II Rheumatoid arthritis Smolen et al. (2014)
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comparable between secukinumab and placebo groups in
psoriasis but in rheumatoid arthritis AEs rate was higher in
secukinumab cohort (Patel et al. 2013). Dick et al. (2013)
described three clinical trials in third phase which evalu-
ated the effectiveness of secukinumab in treatment of
noninfectious uveitis. They did not notice any statistical
significance between secukinumab and placebo groups.
Hueber et al. (2012) published unexpected results
describing ineffectiveness of secukinumab in controlling
severe Crohn’s disease. Additionally they revealed higher
rates of adverse events in mAb treated group comparing to
placebo series.
An anti-IL6 receptor antibody (tocilizumab) and an IL-1
receptor antagonist (anakinra), which were approved for
therapy of human autoimmune diseases, also target
development and function of Th17 cells (Samson et al.
2012). ADACTA study displayed that tocilizumab is more
effective in RA monotherapy than adalimumab (TNF
antagonist) while AMBITION study revealed that tocili-
zumab may be considered as the first biological drug more
effective than methotrexate (Herna´ndez et al. 2013).
Samson et al. (2012) demonstrated that tocilizumab may
correct of imbalance between Th17 and Treg cells in
patients with RA. It is worth emphasizing that it was well
tolerated after subcutaneous or intravenous administration
(Burmester et al. 2014; Kivitz et al. 2014). Anakinra is the
first IL-1R antagonist accepted in therapy of RA and it
binds to both IL-1a and IL-1b (Cavagna and Taylor 2014).
Tofacitinib (CP-690,550) is a novel JAK/STAT inhi-
bitor directly suppressing the production of IL-17 and IFN-
c and its effect is associated with decreased concentration
of IL-6 (Ghoreschi et al. 2011; Maeshima et al. 2012). This
Janus kinase inhibitor was proved to enhance clinical status
of patients with RA in randomized, double-blind, placebo-
controlled phase 2a trial (Coombs et al. 2010).
Olokizumab, sarilumab, and sirukumab are some other
drugs using blocade of IL-6 pathway in their interactions.
The first is a humanized anti-IL-6 antibody, which in 2b
phase clinical trial was proved to be as effective as toci-
lizumab in therapy of RA (Tanaka and Mola 2014).
Sarilumab, a human mAb directed against IL-6Ra, can also
improve symptoms of RA, which was showed in the sec-
ond phase clinical trials (Huizinga et al. 2014). However, it
was shown to be ineffective in ankylosing spondylitis
therapy (Sieper et al. 2014). The last drug—sirukumab
(anti-IL-6 mAb)—was also assessed in the second phase
clinical trials in RA. In results the researchers noted an
improvement of clinical status of patients treated with
sirukumab when compared with placebo group (Smolen
et al. 2014).
Furthermore, Eggleton et al. (2011) presented that a
greater proportion of Th17 cells isolated from the periph-
eral blood of RA patients expressed CD20 in contrast to
healthy individuals. These cells may represent an addi-
tional target for popular anti-CD20 therapies.
Conclusions
Th17 cell population has given immunologists and clini-
cians some new possibilities. Researchers exploring
molecular pathways connected with Th17 cells try to find
more effective therapies of autoimmune disease. Whether
biological drugs based on inhibition of Th17 dependent
pathways will emerge as front-line therapies for autoim-
mune and chronic inflammatory diseases is still unclear.
The data from phase three clinical trials are moderately
encouraging but thus far not overwhelming when consid-
ered alongside with other existent or developing
therapeutics.
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